A randomized trial of botulinum toxin A for treatment of drooling
- 11 November 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 61 (9) , 1279-1281
- https://doi.org/10.1212/wnl.61.9.1279
Abstract
The authors compared the efficacy of three different doses (18.75, 37.5, and 75 MU per parotid gland) of botulinum toxin A (BTX-A; Dysport, Ipsen Pharma, Germany) injections vs vehicle in patients with sialorrhea (n = 32) using a single-center, prospective, double-blind, placebo-controlled dose-finding study. The primary endpoint was achieved with 75 MU BTX-A without treatment-related adverse events, suggesting BTX-A is a safe and effective treatment for patients with sialorrhea.Keywords
This publication has 5 references indexed in Scilit:
- Botulinum toxin A (BoNT‐A) for spasticity in adults. What is the evidence?European Journal of Neurology, 2002
- Efficacy and safety of a standardised 500 unit dose of Dysport ® (Clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group studyZeitschrift für Neurologie, 2001
- Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2000
- Botulinum toxin A as treatment for drooling saliva in PDNeurology, 2000
- Four-Duct LigationA Simple and Effective Treatment for Chronic Aspiration From SialorrheaJAMA Otolaryngology–Head & Neck Surgery, 1999